Crossject Société Anonyme (CRJTF) Stock Price, News & Analysis

Company Overview

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Key Stats

• Today's Range: $3.25 to $3.25
• 50-Day Range: $3.25 to $3.25
• 52-Week Range: $3.25 to $3.25
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRJTF Stock Analysis - Frequently Asked Questions

How have CRJTF shares performed this year?

Crossject Société Anonyme's stock was trading at $3.25 at the start of the year. Since then, CRJTF shares have increased by 0.0% and is now trading at $3.25.
View the best growth stocks for 2025 here.

When did Crossject Société Anonyme's stock split?

Crossject Société Anonyme's stock split on Monday, January 3rd 2022. The 2-1 split was announced on Monday, January 3rd 2022. The newly minted shares were payable to shareholders after the market closes on Monday, January 3rd 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How do I buy shares of Crossject Société Anonyme?

Shares of CRJTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTC
• Sector: Medical
• Industry: Medical Specialties
• Sub-Industry: N/A
• Current Symbol: OTC:CRJTF
• CUSIP: N/A
• CIK: N/A
• Web: www.crossject.com
• Phone: 33.3.80.54.98.50
• Fax: N/A
• Employees: 94
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A